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Abstract: A novel approach was developed for the coencapsulation of an anti-HIV drug (tenofovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL)
assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe3O4) nanoparticles (10±3 nm) were synthesized and characterized. The LbL technique was used to achieve a
sustained release profile, and application of 2 bilayers ([tenofovir+dextran sulphate]2+vorinostat)
to magnetic nanoparticles resulted in a 2.8 times increase in drug (tenofovir) loading and also
resulted in an increase in the drug release period by 30-fold, with 100% drug release in sustained
manner over a period of 5 days with the simultaneous stimulation of latent HIV expression.
Nanoformulation showed a good blood–brain barrier transmigration ability (37.95%±1.5%)
with good in vitro antiviral efficacy (~33% reduction of p24 level) over a period of 5 days
after HIV infection in primary human astrocytes, with good cell viability (.90%). Hence, LbL
arrangements of drugs on magnetic nanoparticles provides sustained release and, therefore, may
improve the patient’s adherence to therapy and lead to better compliance.
Keywords: layer-by-layer, magnetic nanocarriers, blood–brain barriers, neuroAIDS, sustained
release, anti-HIV drug, latency
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Ever since the introduction of combination antiretroviral therapy (ART), HIV-infectionrelated morbidity and mortality have dramatically decreased. However, none of the
currently available antiretroviral agents provides a cure. HIV infection has now become
a chronic disease requiring a lifelong commitment to daily oral treatment.1 Highly
active ART (HAART) comprises complex regimens that require strict adherence to
complicated treatment schedules, and the quality of treatment depends on the patient’s
adherence to the recommended regimens. Antiretroviral adherence is the second
strongest predictor of progression to AIDS and death, after CD4 count.2,3 Incomplete
adherence to ART, however, is common in all groups of treated individuals. The average rate of adherence to ART is approximately 70%, despite the fact that long-term
viral suppression requires near-perfect adherence.4,5 Most antiretroviral drugs have
a short half-life and, in turn, need be in circulation constantly to control the virus
replication. It is believed that missing a medication dose even once can provide an
opportunity for viruses to replicate such that a medication-resistant HIV strain may
develop. Patient nonadherence can be a pervasive threat to health and well-being and
can carry an appreciable economic burden. Despite all the best intentions and efforts
on the part of health care professionals, a patient’s noncompliance in the case of HIV
therapy (HAART) is very high.4 As per clinical trial data on HIV drugs, results show
that missed doses of antiretroviral agents were most likely to occur because of forgetting (43%), sleeping through a dose (36%), being away from home (32%), changing
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one’s routine (27%), being too busy to take the dose (22%),
feeling sick (11%), and experiencing depression (9%). 5,6
These shortfalls of nonadherence have serious and detrimental effects from the perspective of disease management
and treatment.7 Although no single intervention strategy can
improve the adherence of all patients in HIV, and attempts
to improve patient adherence depend on a set of key factors,
reduction of dosing frequency can lead to efficient patient
compliance.
HAART only helps in suppressing HIV replication, but
it does not clear virus from infected individuals. Various
reservoirs of replication-competent HIV have been identified that may contribute to this persistence. Several attempts
have been made to clear the latent HIV reservoir, but these
attempts have not been successful in eliminating all latently
infected cells or in preventing virus rebound on cessation
of therapy.8 In addition, efforts should be made to target
hidden latent virus in the body’s sanctuaries, such as the
brain, which serves as one of the sources of virus production
to the periphery. Vorinostat, a histone deacetylase inhibitor, has shown great promise to break latency in CD4+ T
cells, and recent studies also have shown that other agents
(tumor necrosis factor, interleukin 1β, and bryostatin) are
being used as HIV-reactivating agents to break latency; nevertheless, the effect of vorinostat on the neuronal reservoir
has not yet been established.9,10 Scientists are exploring a
variety of strategies in the hope of either completely eradicating HIV from the body (a sterilizing cure) or reducing
it to such a low level that the immune system can maintain
control without antiretroviral drugs (a functional cure).
Among these strategies are agents that flush HIV out of
latent reservoirs, drugs that keep hidden virus permanently
inactive, and immune-strengthening therapies that protect
cells from infection. The general scientific consensus is
that a cure will likely require a combination approach.
In spite of significant advances in HAART, the elimination of HIV-1 reservoirs from the central nervous system
remains a formidable task.11–13 This is mainly attributed to
the inability of ART to penetrate the blood–brain barrier
(BBB) and deprived the brain from the drug effects.10,14–16
Long-acting formulations of therapeutic agents have been
used to improve adherence and prevent issues such as
missing doses or treatment fatigue to prescribed medication in a number of different fields such as contraception,
male hypogonadism, and schizophrenia, with demonstrable
success.17 Therefore, as suggested earlier, the sustained
release formulation of latency-breaking agents, together
with antiretroviral drugs, could serve a multifunctional
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purpose and help eradicate HIV. Where sustained drug
release may cause reduced adherence, a combination of
latency-breaking and anti-HIV agents could eradicate a viral
reservoir. The practice of nanotechnology in nanomedicine
has shown exciting prospects for the development of a novel
drug delivery system to achieve the desired therapeutic levels of anti-HIV drugs and HIV-reactivating agents across the
BBB.18–21 In a nutshell, we need to deliver the drugs across
the brain, activate the latent HIV, and subsequently release
HIV drugs from the carrier at a constant rate for a longer
period to increase therapeutic adherence and eradicate the
activated HIV reservoir without hampering the integrity of
the BBB. Considering these scenarios, we have developed
a novel, nanoengineered layer-by-layer (LbL) assembly of
an anti-HIV drug (tenofovir) and a latency-breaking agent
(vorinostat) on ultrasmall magnetic nanoparticles (MNPs) to
achieve the sustained release of the drug for 5–7 days. The
movement of MNPs can be “remote controlled” for its effective penetration across the BBB by applying an external
magnetic force, as shown in the schematic in Figure 1.
Complementarily, LbL arrangements of drugs on MNPs
will provide sustained release, therefore improving bioavailability and the patient’s adherence to medication. The
formulation assembly and underlying drug release mechanism from nanoengineered assembled MNP is represented
in Figure 2.
Our current work is a proof-of-concept study demonstrating that an HIV latency-breaking agent (vorinostat) can be
packaged into nanoparticles in conjunction with an antiretroviral drug (tenofovir). We have designed a formulation that
uses nanotechnology to simultaneously reactivate and kill
HIV in a sustained manner for 5 days across the BBB, which
will be beneficial for the treatment of neuroAIDS. Therefore,
our work provides a platform for more effective HIV therapy
and possible future eradication of the virus.

Materials and methods
Synthesis of ultrasmall MNPs
The ultrasmall Fe3O4 MNPs were synthesized according
to the coprecipitation method proposed by Sun et al22 with
minor modifications. All glassware was cleaned overnight
by aqua regia before being used for the reactions. Briefly, a
solution of 3 mL FeCl3 (0.487 g dissolved in 2 mol/L HCl)
and 10.33 mL H2O was stir-mixed with 2 mL Na2SO3 (0.126 g
in 2 mL of water) drop by drop over the course of a minute.
On the change in color from yellow to red-light yellow,
this solution was mixed into 80 mL NH3+H2O (0.85 mol/L)
under vigorous stirring. A black precipitant quickly formed,
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Figure 1 Nanoformulation delivery across the blood–brain barrier (BBB).
Notes: Proposed schematic of magnetic nanoparticle-based antiretroviral drug delivery across the BBB under the influence of an external noninvasive magnetic force.

which was allowed to crystallize further, for approximately
30 minutes, under continuous stirring. The suspension was
washed, and formation of stable MNPs was achieved by
adjusting the pH from 3.0 to 7.5 and the temperature from
90°C for first 5 minutes to 100°C for about 1 hour. A change
in color from black to reddish-brown suggests the formation
of compact MNPs, which are washed with water at least three
times by the decantation method.

Characterization of MNPs and drug
efficiency: X-ray diffraction and
transmission electron microscopy analysis
Structural conformation of MNPs was determined by
Shimadzu XRD-7000 diffractometer (Shimazdu, Tokyo,
Japan). Transmission electron microscopy of MNPs was
performed with the Phillips CM-200 200 kV transmission
electron microscope operated at 80 kV. In brief, one drop
of MNPs was spread on carbon support film on 400 mesh
Cu grids (type B; Ted Pella, Inc., Redding, CA, USA). For
better contrast during transmission electron microscopy
imaging, samples on the grid were negatively stained
with phosphotungstic acid (2.0% w/v; pH 6.4) and dried
at room temperature. The size distribution and surface
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charge measurement of MNPs were carried out at 25°C in
dynamic laser scattering (Zetasizer NanoZS, Malvern). The
measurement of super paramagnetism was carried out by
a classical vibrating sample magnetometer (Model 4 HF
VSM, ADE, Lowell, MA, USA). The magnetic hysteresis
loops of the Fe3O4 particles were measured between +1,200
and −1,200 Oersted at room temperature.

Time kinetics and drug-binding isotherm
on MNPs
For determining the time kinetics of direct binding of tenofovir on MNPs, 1 mg/mL tenofovir solution to 1 mg MNPs was
incubated in PBS buffer (pH 7.4) for 0.5, 1, 1.5, and 2 hours
at room temperature. The amount of bound drug or percentage binding to the MNPs was determined by estimating the
concentration of tenofovir in unbound fraction (supernatant)
of the mixture by the spectrophotometric method at an
ultraviolet absorbance of 260 nm. In addition, the effect of
different drug concentrations (1–4 mg/mL) with respect to
drug binding was calculated. For vorinostat, time kinetics
and percentage drug binding were calculated as described
earlier, and calculated using ultraviolet spectrophotometry
at of 240 nm.
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Figure 2 Formulation assembly and drug release mechanism.
Notes: (A) Schematic representation of formulation design. (B) Simplified illustration of the drug release mechanism from magnetic layer-by-layer assembled nanocarriers.
(i) Diffusion-based drug release through pores. (ii) Drug release via surface hydrolysis of polymer chains of polyelectrolyte assembly.

LbL coatings on nanocarriers
A nanoengineered LbL self-assembly technique was used
for nanoparticle coatings, as described by Decher.23 The
polyelectrolyte pairs used for this experiment were dextran
sulphate (polyanion: 2 mg/mL in 0.15 M NaCl; molecular
weight, 500,000) and tenofovir (polycation: 1 mg/mL in PBS;
molecular weight, 287.213 g/mol). In brief, a solution of
2 mg/mL concentration of dextran sulphate sodium (DS) was
prepared with 0.15 M NaCL, with pH adjusted to 7.4. For the coating, 100 µL DS was added to 1 mg drug-loaded MNPs and kept
at room temperature for 20 minutes with intermittent shaking.
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The nanoparticles were then centrifuged at 2,500 rpm
for 3 minutes to separate them from the unreacted DS solution
and were washed with Milli-Q water. Later, 100 µL (1 mg/mL)
positively charged drug (ie, tenofovir) was added for secondlayer deposition to nanocarriers and held for 20 minutes
of intermittent shaking. Finally, coated nanocarriers were
washed twice with distilled water, using centrifugation.
A similar process can be repeated two times to have 2 bilayer
coatings on MNPs, and the surface charge of the MNPs was
measured, using the zeta potential analyzer, after rinsing
and before the addition of each layer. Finally, a vorinostat
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(concentration, 0.05 mg/mL) layer was deposited to a bilayer
(tenofovir+DS)2 system. The final assembled nanoformulation was washed with distilled water, using centrifugation,
and used for release studies.

In vitro drug release pharmacokinetic
study
In vitro drug release studies were performed on uncoated
MNPs and polyelectrolyte-coated assembled nanoformulation. Drug-loaded uncoated and coated MNP formulations
were transferred to an Eppendorf tube containing 150 µL
0.01 M PBS buffer (pH 7.4). The samples were incubated
at 37°C in an incubator, and at preset interval times (every
15 minutes), the release medium was collected and replaced
with fresh buffer solution to maintain the sink condition.
The cumulative percentage drug release data were obtained
using amount of drug release from the total drug content and
was determined spectrophotometrically at a λmax of 260 and
240 nm for tenofovir and vorinostat, respectively. Statistical
analysis of the data was performed using analysis of variance
(single factor). Difference was considered significant when
P,0.05.

Intracellular uptake analysis
Primary human astrocytes (HAs) were seeded on cover
slips in six-well plates with a concentration of 1×106 cells.
After 24 hours, cells were treated with an equal quantity of
nanoformulation in the presence and/or absence of external
magnetic forces for 6 hours. Cells were rinsed three times
with PBS and fixed with 4% paraformaldehyde in PBS for
30 minutes at room temperature. Cover slips were mounted
on the slides with Prolong®Gold antifade reagent (Invitrogen, USA), and fluorescent intensity was detected using
a TCS SP2 Confocal Laser Scanning Microscope (Leica
Microsystems, Wetzlar, Germany).24 Confocal images were
obtained at 488 nm with an argon-ion laser with objective
lens at 20× with electronic zoom settings. To quantify the
cellular uptake of nanoparticle levels, flow cytometry was
used.25 HAs were treated with different concentrations of
fluorescein isothiocyanate (FITC)-tagged nanoformulation
(50, 100, and 200 µg/mL). The cells were then harvested at
24 hours after treatment and were counted; equal amounts of
cells (1×106) were aliquoted in 12×75 mm polystyrene falcon
tubes (catalog 352058; BD Biosciences, San Jose, CA, USA)
and fixed with Cytofix solution (BD Bioscience). Cells were
acquired on an Accuri C6 flow cytometer (BD Accuri, Ann
Arbor, MI, USA) and analyzed with FlowJo software (Tree
Star, Inc., Ashland, OR, USA). A total of 10,000 events were
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collected for each sample. Cells were gated on the basis of
cells with and without nanoformulation controls. Cells positive for nanoformulation are shown in Figure 8 as colored
histograms with shifted mean fluorescence intensity (MFI)
compared with controls.

In vitro BBB preparation and
transmigration assay
Primary human brain microvascular endothelial cells and
HA cells were cultivated as per the provider’s recommendations (ScienCell Research Laboratories, CA, USA). The
BBB model was established as described by Persidsky et
al.26 In brief, the in vitro BBB model was developed in a
bicompartmental transwell culture plate (product 3415;
Corning Life Sciences, Mexico). The upper chamber of
this plate is separated from the lower one by a 10 µm thick
polycarbonate membrane possessing 3.0 µm pores. In a
sterile 24-well cell culture plate with a pore density of 2×106
pores/cm2 and a cell growth area of 0.33 cm2, 2×105 human
brain microvascular endothelial cells and HAs were grown
to confluence on the upper chamber and underside of the
lower chamber, respectively. To access the effect of MNP
nanoformulation on the integrity of the in vitro BBB model,
after transmigration assay, paracellular transport of FITCdextran was measured.15 Briefly, 100 mg/mL FITC-dextran
(Sigma-Aldrich, St Louis, MO, USA) was added to the upper
chamber of the inserts and further incubated for 6 hours. Samples were collected from the bottom chamber after 6 hours,
and relative fluorescence was measured at excitation wavelength 485 nm and emission wavelength 520 nm, using a
Synergy HT multimode microplate reader (BioTek Instruments, Inc., Winooski, VT, USA) multimode microplate
reader instrument. FITC-dextran transport was expressed as
percentage FITC-dextran transported across the BBB into
the lower compartment compared with negative control.
Intactness of in vitro BBB was determined by measuring the
transendothelial electrical resistance (TEER), using Millicell
ERS microelectrodes (Millipore). Transmigration study of
drug-loaded MNP was conducted on the fifth or sixth day
of the BBB culture, when ideal integrity of this membrane
was achieved, as established by TEER measurement. MNP
formulation was added to the apical chamber and incubated at
37°C in the presence or absence of a magnetic force of 0.08 T
placed externally, below the transwell basolateral chamber.
MNP nanoformulation was collected from lower chambers
at 6 hours, and percentage transmigration was analyzed at
different points, using an ammonium thiocyanate-based
photometric assay.18
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Cytotoxicity assay
Cytotoxicity was assessed by MTT cell viability assay, using
a CellTiter 96®Aqueous one-solution cell proliferation assay
kit (catalog G3580; Promega, USA).19 HAs were seeded in
96-well tissue plates at a density of 5×103 cells per well. After
24 hours of incubation at 37°C, culture medium was replaced
with 100 µL fresh media containing different concentrations of Fe3O4 (50–250 µg/mL). Twenty microliters MTT
solution (5 mg/mL in PBS) were added into each well after
24 hours posttreatment and incubated at 37°C for 2 hours.
Finally, 100 µL stop solution (20% sodium dodecyl sulfate
in 50% dimethyl formamide) was added into each well, and
absorbance was recorded at 550 nm by a microplate reader
(Synergy HT; BioTek Instruments, Inc.).

Activation of latent HIV, using vorinostat
and in vitro antiviral efficacy of the
nanoformulation
To confirm the activation of latent cells and check the antiviral efficacy of the drug after the magnetic-triggered release
process, we conducted a p24 antigen estimation. The cells
were activated by treating them with polybrene (10 µg/mL)
for 6 hours before the infection. HAs (10×106 cells) were
infected with HIV-1Ba-L (catalog #510; National Institutes
of Health AIDS Research and Reference Reagent Program)
overnight, as described by Atluri et al,24 washed with PBS and
returned to culture with and without standard drug solution
(tenofovir and vorinostat) or drug-loaded nanoformulation at equimolar concentrations. The culture supernatants
were quantitated for p24 antigen, using an enzyme-linked
immunosorbent assay kit (ZeptoMetrix, NY, USA) on the
third, fifth, and seventh days postinfection, expressed as
picograms per milliliter.

Statistical analysis
Experiments were performed at least three times in duplicate, unless otherwise indicated in the figure legends. The
values obtained were averaged, and data are represented as
the mean ± standard error. All the data were analyzed using
GraphPad Prism software. Comparisons between groups
were performed using one-way analysis of variance. Differences were considered significant at P#0.05.

Results
Formulation characterization and drugrelease kinetics
Ultrasmall magnetite nanoparticles were prepared and characterized for size, shape, crystallinity, and drug loading.
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Transmission electron microscopy shows that nanoparticles
were in the range of 10±3 nm, as shown in Figure 3A, with
excellent dispersion properties (polydispersion index .0.81)
in aqueous medium. In addition, the effect of drug loading
and LbL deposition on MNP with respect to its hydrodynamic
diameter also was determined (data shown in Figure S1).
Magnetic hysteresis loops for MNP displayed strong magnetic
behavior (exhibited by a superparamagnetic property with no
coercivity and remanence), when measured between +1,200
and −1,200 Oersted at room temperature (as shown in
Figure 3B). The crystal structure of synthesized magnetite
particles was confirmed by X-ray diffraction spectroscopic
measurement (Figure 3C). The X-ray spectrum consists of
magnetite-specific peaks that correspond to 220, 311, 400,
511, and 440 planes. The encapsulation efficiency of tenofovir-loaded (35%±8%) and vorinostat-loaded (25%±8%)
uncoated MNPs were calculated.
LbL assembly deposition was confirmed using zeta potential analysis; results show that the zeta-potential value for
uncoated MNPs coated with tenofovir was +8.62±1 mV, which
reversed on adsorption of drug DS coating to −29.3±3 mV and
kept on reversing on subsequent layer deposition, as shown
in Figure 3D, thus confirming that layer deposition is taking
place, as desired and predicted. Results showed (Figure 3E)
that application of 1 layer of DS leads to 1.9 times
(32–62.5 µg/mg MNPs) higher drug encapsulation and, in
the case of 2 bilayers (2BL), loading increases to 2.8 times
(32–90.7 µg). The pharmacokinetic release studies show
that uncoated MNPs release 100% drug in 4 and 7 hours,
respectively, for tenofovir and vorinostat. The application
of LbL assembly (1 layer and 2BL) increases the tenofovir
release duration from 48 to 120 hours, as shown in Figure 4
(inset shows the initial 4 hour burst release data for all type
nanoformulations). To confirm the structural and functional
integrity of the drug after the release process, mass spectrometry analysis (details given in Figure S2) of the drug
(tenofovir) was performed before (standard drug) and after
the release (results shown in Figure S3).

In vitro BBB characterization and
formulation transmigration assay
The BBB transmigrability of the plain MNPs and MNPs-2BL
drug-loaded nanoformulation was evaluated using an in vitro
human BBB model. The intactness of grown BBB was determined by TEER values. After the TEER determination, MNP
nanocarriers were subjected to different wells, either in the
presence or the absence of external magnetic force. As shown
in Table 1, initial TEER values of all treatment groups were
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([magnetic nanoparticle+tenofovir]2+vorinostat). (B) Zeta potential analysis for confirmation of drug-layer deposition. (C) Effect of dextran sulphate sodium layer coating
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Table 1 Transendothelial electrical resistance values of the in vitro blood–brain barrier model before and after treatment of nanocarriers
(coated and uncoated) in the presence and absence of external magnetic force
Transendothelial electrical
resistance values, ohms/cm2

Untreated well
(control)

Plain magnetic
nanoparticles

Drug-loaded magnetic
nanoparticles

Two bilayer coated
magnetic nanoformulation

Before treatment
After magnetic treatment

198.2±7.9
192.6±5.8

201.2±6.5
198.4±7.5

197.2±5.9
190.2±6.2

194.3±5.6
196.2±4.3

sample compared with ~100% in the case of negative control
(without any BBB cells), thus showing that transmigration
of MNP nanoformulation under external magnetic field does
not affect the BBB integrity

similar to standard 200±5 ohms/cm2. A schematic of proposed
mechanisms of transmigration across BBB has been depicted
in Figure 1. As expected, there was no difference found in the
formulations value (results shown in Table 1) when compared
with uncoated and unloaded MNP carriers.
Formulation ability with respect to BBB transmigration
was verified by measuring the iron concentration after application of the external magnetic field. As evident from Figure 5A,
40%±3% of plain MNP versus 31.8%±3.5% of final nanoformulation ([MNP+tenofovir]2+vorinostat) crosses the BBB in
the presence of 0.8 T magnetic fields in 6 hours.
Without application of external magnetic force, only
2%±1.5% of the formulations were able to cross the BBB
in 6 hours (result not shown). Furthermore, the integrity of
BBB was evaluated using paracellular transport of FITCdextran, as described earlier,27 where the FITC molecule
was used as a detection moiety to confirm the membrane
intactness. Figure 5B shows that only 7–8%±2% of the
FITC molecule was detected in the transmigration (apical to
basolateral chamber) in the entire nanoformulation treatment

B

To evaluate the cytotoxicity of nanoformulation, we performed the MTT cytotoxicity assay on HAs. Results show
(Figure 6) that treatments with different concentrations
(50–200 µg/mL) of nanoengineered MNP nanoformulation do not show any cytotoxicity, and the percentage of
viable cells was similar to untreated control, suggesting
that doses of nanoformulation are nontoxic and have no
significant safety concerns. Experiments were also conducted in neuronal cells and peripheral cells, and there were
no cytotoxic effects observed (data shown in Figure S4 for
neuronal cells).
In addition, the qualitative and quantitative analysis of
formulation, in terms of cellular uptake, was performed
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Figure 5 In vitro blood brain barrier model characterization.
Notes: (A) Magnetic nanoparticle (MNP) nanoformulation transmigration across an in vitro blood–brain barrier model. Magnetic nanoformulation was added in the upper
chamber of the blood–brain barrier model with a magnet placed underneath for the duration of experiment. At 6 hours after plating, migrated plain MNPs and nanoformulations
were calculated for iron content in the lower chamber. Results are expressed as mean ± standard error of three independent experiments. Statistical significance was
determined using unpaired Student’s t-test. (B) Effect of nanoformulation on fluorescein isothiocyanate-dextran transport in the blood–brain barrier model. Fluorescein
isothiocyanate-dextran transport was measured in blood–brain barrier model after 6 hours of magnetic treatment. FITC-dextran was added on the upper chamber of the
insert. After 6 hours of incubation, relative fluorescence units from the basal chambers of the inserts were measured. Results were expressed as percentage fluorescein
isothiocyanate-dextran transport with respect to the untreated control cultures (negative control = no cell and positive control = with cells) and represented as mean ±
standard error of independent experiments. NS indicates when P-value was found to be more than 0.05, then the result would be considered statistically not significant.
Abbreviation: FITC, fluorescein isothiocyanate.
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Figure 6 Cell viability of human astrocytes with magnetic nanoparticle nanoformulation.
Notes: Results show the percentage of cells viable after treatment with different concentrations of nanoformulation (50–200 µg/mL) for 24 hours.

using the same concentrations (50–200 µg/mL). Confocal
microscopy was used to visualize the MNP nanoformulation particle uptake at different points (range, 6–24 hours).
Figure 7 represents the cellular uptake of formulation in HAs
after 6 hours of nanoformulation treatment at 100 µg/mL
concentration.
For quantitative analysis, a flow cytometer was used.
Our results show a concentration-dependent increase in the

p ercentage of cells positive for FITC-tagged nanoformulation: As the concentration increased from 50 to 200 µg/mL,
there was 1.25-fold (ie, 35.7% to 44%) increase in the percentage of cells positive for FITC-tagged nanoformulation, as
shown in Figure 8 after 24 hours of treatment. Furthermore,
when we analyzed the MFI, as shown in the legend, there
was a significant concentration-dependent increase in MFI;
for instance, a MFI of 59,395 was observed for 50 µg/mL

BF image

DAPI

NP

Composite

Figure 7 Cell uptake of fluorescein isothiocyanate-tagged magnetic nanoparticle nanoformulation (concentration, 100 µg/mL) in primary human astrocyte after 6 hours
of treatment.
Notes: Composite image shows green (drug-loaded 2-layer formulation) and blue (cell nuclei) fluorescence inside the cells, and thus confirms the cellular uptake of the
nanoformulation. Images were taken at 10× magnification (inset image magnifications, 20×), using fluorescence microscopy (Leica, Wetzlar, Germany).
Abbreviations: BF, bright field image; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride; NP, nanoparticle.
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Cell +100 µg/mL
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10,000
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80
60

200 µg/mL

80

FL1:nanoparticles
Figure 8 Quantitative analysis of fluorescein isothiocyanate-tagged magnetic nanoparticle nanoformulation after 24 hours of treatment in primary human astrocytes by flow
cytometry.
Notes: Data suggest that an increase in concentration from 50 to 200 µg/mL leads to an increase in the percentage of cells positive for fluorescein isothiocyanatetagged nanoformulation, as well as an increase in mean fluorescence intensity. Ten thousand events were collected for each sample. Cells were gated on the basis of cells
without nanoformulation (brown line histogram) and nanoformulation alone (blue dotted-line histogram) controls. Cells positive for nanoformulation are shown as colored
histograms with shifted mean fluorescence intensity compared with controls. Colored histograms on (A–C) represent cells treated with 50 (blue), 100 (red), and 200 (green)
µg/mL fluorescein isothiocyanate-tagged nanoformulation, which shows a 35.7%, 40%, and 44% increase in cells positive for nanoformulation and 59,395, 77,380, and 139,109
mean fluorescence intensity, respectively. Histograms on (D) show an overlay of all three concentrations (50, 100, 200 µg/mL).
Abbreviations: FL, fluorescence; MNP, magnetic nanoparticle.

concentration, which increased to 139,109 (ie, 2.3-fold)
when concentration was increased to 200 µg/mL. Overall,
it is relevant to point out that the increase in MFI correlated
with an increase in the percentage of cells positive for
FITC-tagged nanoformulation, and that both increases were
concentration-dependent.

Latency-breaking and in vitro antiviral
efficacy of the nanoformulation
Latency-breaking and antiviral efficacy of the nanoformulation was determined via quantification of p24 antigen in the
HA infection model.19 Our group reports for the first time
that vorinostat significantly activates latent HIV infection
in the neuronal cells.28 Different concentrations (0.5–5 µM)
of vorinostat (solution phase) were tested for the latencybreaking ability; the results showed that a 1 µM concentration
yields a significant difference in p24 value (data shown in
Figure S5) and was used for the final formulation development.
To confirm the efficacy of the nanoformulation after the
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magnetic-triggered release process after 24 hours, we conducted a p24 viral replication assay, the results of which
showed (Figure 9) that standard tenofovir (1 mg/mL solution), and MNPs-2BL nanoformulation showed equal p24
inhibition efficacy after the third day postinfection, thus
suggesting that the integrity and efficacy of the drug are not
lost after external magnetic application.
The results show a good latency-breaking ability for
vorinostat-loaded MNPs (20.5% increase) when compared
for p24 levels, with respect to positive control (HIV-infected
HA cells), as shown in Figure 10 on day 1 of nanoformulation treatment. The sustained-release ability of the finally
assembled nanoformulation ([MNP+tenofovir]2+vorinostat)
was also evaluated over a treatment period of 5 days in the
HA model.
Our results showed that there was a significant suppression of viral load (~33%; 390–260 pg/mL) reduction of p24
level found after 7 days of HIV infection with 5 days of
nanoformulation treatment, which clearly shows that drug
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Figure 9 p24 study to prove that the magnetically triggered release does not affect
the inhibition efficacy of the drug (tenofovir) in HIV replication.
Notes: Release drug and standard drug (1 mg/mL) used for efficacy assay in human
astrocytes. Treatment was done for 24 hours, and results were analyzed via p24
antigen estimation, using enzyme-linked immunosorbent assay on the fifth day of
infection and expressed as picograms per milliliter.
Abbreviations: 2BL, 2 bilayers; Std, standard; NS, not significant.

is getting released in sustained manner over a period of
5 days and is able to activate latent cells and suppress the
viral replication.

Discussion
Adherence to dosing regimens is a critical issue for HIV
treatment and its prevention. It has been hypothesized that
the development of approaches eliminating or reducing the
effect of individual adherence could increase the efficacy of
treatment strategies and provide for the prevention of HIV
transmission. Considering this scenario, there is a need to

develop new and innovative sustained-release antiviral
formulations for better treatment of HIV (peripheral or
central nervous system) disease and the prevention of HIV
transmission and acquisition. Magnetite (Fe3O4) is the most
commonly used MNP in the field of biomedicine, mainly
because of its biocompatibility. In this study, ultrasmall
MNPs were developed by the coprecipitation method (the
main advantage of this method is its circumstance-friendly
and cost-effective method of preparation on the nanoscale)
and tested for their drug-loading, in vitro release pharmacokinetics, cytotoxicity, and in vitro antiviral replication
efficacy in central nervous system cells. The most important
parameters affecting release behavior were identified and
optimized. The superparamagnetism can be used for simultaneous monitoring and quantitation of MNP (specific or
nonspecific) distribution to various tissues.
Distribution of charge on the surface of synthesized
MNPs was determined by measuring the zeta potential. The
zeta-potential values clearly demonstrated that the surface
charge of the MNPs reverses on coating of alternately
charged moieties (tenofovir/DS coating), proving that
multilayer build-up is taking place. The desired system is
expected to achieve complete release of the drug in 5–7 days
to overcome the problem of frequent dosing and better patient
adherence. To achieve 100% drug release over a period of
1 week with zero-order release kinetics, different amounts
of tenofovir were used for loading. It was observed that drug
loading of MNPs does not increase with increasing the drug
amount to the nanoparticles. In most cases, drugs are either
directly immobilized or loaded on the nanocarrier surface

HIV infected HA (control)

Vorinostat nanoformulation

Tenofovir nanoformulation

Teno+vor nanoformulation

% cell viability

400
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350
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*
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80
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60

200

40
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100

20
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0

120
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*
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Formulation treatment period
Figure 10 Evaluation of antiviral efficacy of nanoformulation in suppressing p24 antigen levels in HIV-infected human astrocytes.
Notes: Nanoformulations were added on the second day after HIV infection (HIV-1BaL) in equimolar concentration. Supernatants were evaluated on third, fifth, and seventh
day postinfection for p24 levels and were checked for its efficacy, along with its percentage cell viability, using MTT assay. Simultaneous incorporation of tenofovir and
vorinostat into the magnetic nanoparticles’ nanoformulation leads to latent virus activation and inhibits viral spread almost comparable to tenofovir nanoformulation. Viral
p24 protein in the culture supernatant was measured by enzyme-linked immunosorbent assay. Error bars indicate the standard deviation of triplicate data points and are
representative of at least three experiments. Dotted lines represent the percentage cell viability; each point represents treatment period. *If mean P-value was found to be
less than 0.05, then the result would be considered statistically significant.
Abbreviations: HA, human astrocytes; Teno, tenofovir; Vor, vorinostat; NS, nonsignificant.
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or tethered via adsorption or immobilization (coating) of
organic/inorganic surfactants (eg, polyethylene glycol).29,30
In either case, attached drugs are exposed to the external
environment and possess the threat of rapid decomposition because of metabolic (enzymatic mainly) activity of
the peripheral circulation (blood) before it could reach the
target.14,18 Even though the nanoparticles have a high surface
area, one of the major limitations in drug delivery is their low
drug-loading capacity, which could be a problem in the development of long-term or sustained-release formulations.
To avoid the abovementioned problems, scientists have
used a hybridization strategy in which nanoparticle formulation is encapsulated in liposomes,18,31 and this nanoformulation has developed as a possible solution, but the limitation
with this technique is that it increases the size of nanoformulation up to +100 nm, which makes the formulation less able
to cross the BBB.32–34 Considering these limitations, we have
proposed, for the first time, the use of LbL methodology23,35
(spontaneous adsorption of alternating layers of positively
and negatively charged species). This technique is simple,
fast, and versatile and helps in loading more drugs as a result
of the electrostatic interaction between oppositely charged
layers. The rate of release can also be adjusted through shell
thickness, which can be controlled according to layer numbers. Another advantage of this thin film nanoengineered
architecture deposition is the precision of layer thickness
control that is within the range of 3–5 nm (each layer),
which helps in maintaining the size of nanoparticles within
the desirable range.
Therefore, to achieve sustained drug release, a LbL selfassembly technique was applied to the MNPs, helping to
reduce the initial burst and prolonging the period of release in
the induction phase without significantly affecting the release
rate. Our results demonstrate that the zeta potential of nanoparticle formulation reversed on the addition of oppositely
charged polyelectrolyte and drug (DS/tenofovir)2 coatings,
causing greater stability of nanoparticles, as indicated by the
greater negative and positive charges. Electrostatic interactions between the nanoparticles and the polyelectrolytes are
the main driving force for multilayer build-up. These interactions seem to be strong enough; otherwise, the adsorbed layers would be removed on the adsorption process of the next
polyelectrolyte layer, as evident by zeta-potential analysis.
Results showed that LbL significantly reduced the tenofovir
initial burst threefold and increased the duration of drug
release (30 times) in the induction phase (4 versus 120 hours).
In the case of vorinostat-uncoated MNP release, there was a
slow release of vorinostat because of its low water solubility
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(7 hours) compared with that of uncoated MNPs loaded with
tenofovir (4 hours).
Cytotoxicity testing of the nanoformulation is highly recommended and is considered one of the most fundamental tests for
biocompatibility. The aim of cytotoxicity studies is to evaluate
the in vitro biocompatibility of a drug-loaded polyelectrolytecoated nanoformulation in different brain cells. Different cellular
aspects were analyzed to determine the cell viability in HAs,
such as cell uptake, adhesion, proliferation, and morphology.
The results provided good evidence of adhesion, growth, and
morphology, with more than 95% of cell viability in cases of
all different concentrations of nanoformulation. Flow cytometer
analysis of cellular uptake shows a concentration-dependent
increase in cell uptake, which is evident from the increase in
mean fluorescence intensity and increased percentage of cells
positive for FITC-tagged nanoformulation. Furthermore, the
effect of the magnetic field on the transmigration ability and
BBB integrity of the formulation was evaluated, and results show
there was no damage to the BBB and that more than 40% of the
nanoformulation crosses the BBB only after the application of
6 hour magnetic field. To achieve higher transmigration of the
formulation, we have optimized the important parameters of
magnetic field and time of application. The results demonstrate
the ability of our nanoformulation system to be efficiently
taken up into the cells and provide a platform with which we
can effectively deliver our cargo of interest (ie, an HIV-latency
activator [vorinostat] and nucleotide reverse transcriptase inhibitor [tenofovir]). The integrity of the release drug after the magnetic field was evaluated using mass spectroscopy and checked
for its antiviral replication efficacy. Our results demonstrate
that free standard drug displays inhibition equal to that of the
released nanoformulation. To test the ability of nanoformulation
([MNP+tenofovir]2+vorinostat) to activate latent virus, we used
the HA cell culture system. In addition, the long-term sustainedrelease behavior was studied directly in the HIV-infected HA
cell culture system. Results were very positive; nanoformulation
can effectively control virus spread up to 5 days in a continuous
manner, while at the same time being able to stimulate latent
HIV expression in HA cells, as evident in the results.

Conclusion
In conclusion, the current work is an in vitro proof of study
demonstrating that latency-breaking agents can be packaged into nanoparticles in conjunction with an antiretroviral
drug. We successfully established the application of the
LbL assembly technique by achieving long-term release
(5 days) across the BBB in a sustained manner. Further, we
combined the synergistic effect of vorinostat and tenofovir
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in a single nanoformulation and demonstrated the ability of
nanotechnological approaches to provide improved methods
for activating latent viruses and killing them simultaneously.
Novel drug delivery systems such as the one described
here may enhance the future of HIV therapy by using
combination therapy of ARV drugs (ie, [nucleotide reverse
transcriptase inhibitor+nucleotide reverse transcriptase
inhibitor+protease inhibitor] or [nucleotide reverse transcriptase inhibitor+protease inhibitor+integrase inhibitor])
to achieve better efficacy and complete the eradication of
the virus from the central nervous system. In the future,
in vivo studies will be performed using the HIV-infected
severe combined immunodeficiency mouse model to assess
the free drug amount (microdialysis) present in the brain
parenchyma to evaluate the therapeutic efficacy of the
nanoformulation.
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Figure S2 Mass spectrometry analysis.
Note: Mass spectrometry instrumental parameters used for the LC/MSD analyses (General Screening Method).
Abbreviations: LC/MSD, liquid chromatography–mass spectrometry data; temp, temperature; Vcap, capillary voltage; min, minute.
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Figure S3 Mass spectroscopy analysis.
Notes: The number of counts versus the mass-to-charge ratio (standard peak of 288) for (A) the standard free tenofovir (1:10 water dilution); (B) released tenofovir from 1
bilayer formulation (MNP+tenefovir+dextran sulphate); and (C) released tenofovir from 2 bilayers formulation ([tenofovir+dextran sulphate]2+vorinostat). [M+H]+ indicates
protonated molecular ions of the formula in positive ionisation mode.
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Figure S4 Cell viability of neuronal cells (SK-N-MC cells) with MNP nanoformulation.
Note: Results show the percentage of cells viable after treatment with different concentrations of (50–200 µg/mL) for 24 hours.
Abbreviation: MNP, magnetic nanoparticles.
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Figure S5 p24 study to show effect of standard (free drug) vorinostat on HIV replication in human astrocytes.
Note: Different ranges of vorinostat (0.5–5 µm) were used; results show maximum p24 value at 1µM concentration, which is used for the nanoformulation development.
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